HSBC Forecasts Strong Price Appreciation for Pfizer (NYSE:PFE) Stock

Pfizer (NYSE:PFE) had its price target upped by research analysts at HSBC from $29.00 to $32.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. HSBC’s price objective suggests a potential upside of 18.23% from the company’s current price.

PFE has been the subject of several other reports. Citigroup assumed coverage on shares of Pfizer in a research note on Tuesday, December 2nd. They set a “neutral” rating and a $26.00 price target for the company. Barclays assumed coverage on shares of Pfizer in a report on Thursday, February 19th. They set an “underweight” rating and a $25.00 target price for the company. Royal Bank Of Canada started coverage on shares of Pfizer in a research report on Tuesday, February 24th. They issued an “underperform” rating and a $25.00 target price for the company. Morgan Stanley lowered their price target on shares of Pfizer from $32.00 to $28.00 and set an “equal weight” rating on the stock in a research note on Friday, December 12th. Finally, Guggenheim restated a “buy” rating on shares of Pfizer in a report on Wednesday, December 17th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, fourteen have issued a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $28.19.

Pfizer Stock Up 1.7%

NYSE PFE traded up $0.46 on Tuesday, reaching $27.07. The company had a trading volume of 17,383,893 shares, compared to its average volume of 45,810,984. The firm has a market capitalization of $153.90 billion, a price-to-earnings ratio of 19.91 and a beta of 0.47. The company’s fifty day moving average is $26.53 and its 200-day moving average is $25.54. Pfizer has a 1-year low of $20.92 and a 1-year high of $27.94. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.87 and a current ratio of 1.16.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, topping the consensus estimate of $0.57 by $0.09. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.The company had revenue of $17.56 billion during the quarter, compared to analysts’ expectations of $16.93 billion. During the same period in the prior year, the firm earned $0.63 earnings per share. Pfizer’s revenue for the quarter was down 1.2% compared to the same quarter last year. On average, research analysts forecast that Pfizer will post 2.95 earnings per share for the current fiscal year.

Institutional Trading of Pfizer

Institutional investors and hedge funds have recently bought and sold shares of the business. Horizon Financial Services LLC boosted its stake in shares of Pfizer by 174.8% during the 4th quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 645 shares during the period. Godfrey Financial Associates Inc. acquired a new stake in Pfizer during the 4th quarter valued at $26,000. YANKCOM Partnership bought a new position in Pfizer during the fourth quarter worth $28,000. HFM Investment Advisors LLC boosted its position in Pfizer by 61.0% during the fourth quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 427 shares during the period. Finally, Grey Fox Wealth Advisors LLC acquired a new position in shares of Pfizer in the third quarter valued at $29,000. Institutional investors own 68.36% of the company’s stock.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Late-stage clinical win: Pfizer reported that an experimental combination cut risk of disease progression or death by ~40% in a mid‑stage breast cancer trial — a materially positive efficacy signal that could advance a registration path and eventually add oncology revenue if confirmed. Pfizer says experimental breast cancer drug cuts risk of disease worsening in mid-stage trial
• Positive Sentiment: Positive Phase 2 topline for atirmociclib (CDK4 inhibitor): The FOURLIGHT‑1 study met its primary endpoint in second‑line HR+/HER2‑ metastatic breast cancer, supporting Pfizer’s next‑generation CDK4 program and strengthening its oncology pipeline diversification. This boosts long‑term revenue optionality beyond legacy franchises. Pfizer Announces Positive Topline Phase 2 Results for Atirmociclib
• Positive Sentiment: Analyst and investor attention is lifting sentiment: Coverage highlighting Pfizer as a top healthcare pick and renewed retail/institutional interest (mentions from Goldman/BMO and Zacks interest) can support multiple expansion and flows into PFE. Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know
• Neutral Sentiment: Pipeline breadth & defensive moves: Reports note multiple early‑stage starts (new tafamidis tablet, pediatric etrasimod, multivalent pneumococcal vaccine PG4) — positive for long‑term growth but unlikely to move near‑term revenue. Pfizer Trials Highlight Effort To Broaden Future Revenue And Defend Franchises
• Neutral Sentiment: Deal spillover: IP Group’s NAV jump after Pfizer’s Metsera acquisition underscores M&A activity and strategic buys in obesity/other areas; this is indirect confirmation Pfizer is active on BD but not immediate revenue for PFE. IP Group returns to growth as Pfizer deal drives NAV rise
• Negative Sentiment: Key execution risk remains: Commentary reminding investors that Pfizer’s revenue scaled by COVID products has normalized and several blockbusters face exclusivity/lifecycle pressures — a risk to near‑term top‑line growth and valuation if new launches don’t scale. Should You Avoid Pfizer? Here’s the Key Risk to Watch

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.